Rhea N Coler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/944957/publications.pdf

Version: 2024-02-01

66 papers	3,977 citations	126907 33 h-index	123424 61 g-index
67 all docs	67 docs citations	67 times ranked	4387 citing authors

#	Article	IF	Citations
1	It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity. Frontiers in Immunology, 2022, 13, 840225.	4.8	19
2	Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease. Virulence, 2022, 13, 808-832.	4.4	3
3	Diagnostics and the neglected tropical diseases roadmap: setting the agenda for 2030. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 129-135.	1.8	38
4	Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PLoS ONE, 2021, 16, e0247990.	2.5	20
5	Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Scientific Reports, 2021, 11, 9040.	3.3	15
6	Safety and immunogenicity of the adjunct therapeutic vaccine ID93â€ˆ+â€ˆGLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 373-386.	10.7	46
7	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. Journal of Immunological Methods, 2021, 499, 113160.	1.4	12
8	Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant. Microorganisms, 2021, 9, 2253.	3.6	10
9	A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1Â+ÂGLAâ€“SE) in healthy adults. Vaccine, 2020, 38, 1700-1707.	3.8	19
10	Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection. Molecular Therapy - Methods and Clinical Development, 2020, 18, 402-414.	4.1	63
11	Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. Vaccine, 2020, 38, 5256-5267.	3.8	11
12	Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Scientific Reports, 2019, 9, 15560.	3.3	32
13	Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	48
14	The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Neglected Tropical Diseases, 2019, 13, e0007083.	3.0	78
15	Evaluation of the efficacy of RUTI and ID93/GLA-SE vaccines in tuberculosis treatment: in silico trial through UISS-TB simulator. , 2019, , .		6
16	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Cell Reports, 2019, 29, 3060-3072.e7.	6.4	26
17	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53
18	Memory CD4⁺ T cells enhance Bâ€cell responses to drifting influenza immunization. European Journal of Immunology, 2019, 49, 266-276.	2.9	6

#	Article	IF	Citations
19	Safety and immunogenicity of the novel tuberculosis vaccine ID93â€˚+â€˚GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 287-298.	10.7	122
20	The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. Npj Vaccines, 2018, 3, 34.	6.0	135
21	Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines, 2018, 6, 30.	4.4	17
22	A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Molecular Therapy, 2018, 26, 2507-2522.	8.2	109
23	Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection. Frontiers in Immunology, 2018, 9, 295.	4.8	22
24	Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan. Frontiers in Immunology, 2018, 9, 381.	4.8	43
25	A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Scientific Reports, 2017, 7, 46426.	3.3	66
26	A defined subunit vaccine that protects against vector-borne visceral leishmaniasis. Npj Vaccines, 2017, 2, 23.	6.0	31
27	Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines. Vaccine, 2017, 35, 5209-5216.	3.8	18
28	CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination. Vaccine, 2017, 35, 4255-4261.	3.8	33
29	The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. PLoS ONE, 2016, 11, e0146372.	2.5	57
30	A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS ONE, 2016, 11, e0149610.	2.5	28
31	Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis. Parasites and Vectors, 2016, 9, 383.	2.5	30
32	Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice. Vaccine, 2016, 34, 4123-4131.	3.8	25
33	Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants. Scientific Reports, 2016, 6, 39097.	3.3	53
34	Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine, 2016, 34, 2179-2187.	3.8	21
35	Antigen presentation by B cells guides programing of memory CD4⁺ Tâ€cell responses to a TLR4â€agonist containing vaccine in mice. European Journal of Immunology, 2016, 46, 2719-2729.	2.9	15
36	Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites. Vaccine Journal, 2016, 23, 785-794.	3.1	14

#	Article	IF	Citations
37	A structureâ€function approach to optimizing TLR4 ligands for human vaccines. Clinical and Translational Immunology, 2016, 5, e108.	3.8	44
38	Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Scientific Reports, 2016, 6, 19570.	3.3	205
39	Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine, 2016, 34, 2779-2786.	3.8	35
40	Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine, 2016, 34, 586-594.	3.8	85
41	Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. Vaccine Journal, 2016, 23, 137-147.	3.1	41
42	The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age. Biogerontology, 2016, 17, 177-187.	3.9	19
43	Interferon Î³ and Tumor Necrosis Factor Are Not Essential Parameters of CD4⁺T-Cell Responses for Vaccine Control of Tuberculosis. Journal of Infectious Diseases, 2015, 212, 495-504.	4.0	35
44	From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISHâ€F3+GLAâ€SE. Clinical and Translational Immunology, 2015, 4, e35.	3.8	131
45	Vaccination Produces CD4 T Cells with a Novel CD154â€“CD40-Dependent Cytolytic Mechanism. Journal of Immunology, 2015, 195, 3190-3197.	0.8	19
46	Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine, 2015, 33, 6570-6578.	3.8	53
47	Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes. International Journal of Nanomedicine, 2014, 9, 1367.	6.7	27
48	The ID93 Tuberculosis Vaccine Candidate Does Not Induce Sensitivity to Purified Protein Derivative. Vaccine Journal, 2014, 21, 1309-1313.	3.1	14
49	Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization. Journal of Controlled Release, 2014, 177, 20-26.	9.9	51
50	Protection against Mycobacterium leprae Infection by the ID83/GLA-SE and ID93/GLA-SE Vaccines Developed for Tuberculosis. Infection and Immunity, 2014, 82, 3979-3985.	2.2	28
51	Immune Subdominant Antigens as Vaccine Candidates against Mycobacterium tuberculosis. Journal of Immunology, 2014, 193, 2911-2918.	0.8	35
52	A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93. PLoS ONE, 2014, 9, e83884.	2.5	60
53	Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells. Journal of Immunology, 2013, 191, 2514-2525.	0.8	27
54	Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. Journal of Controlled Release, 2013, 172, 190-200.	9.9	101

#	Article	IF	Citations
55	Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment. Journal of Infectious Diseases, 2013, 207, 1242-1252.	4.0	88
56	The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine. Journal of Immunology, 2012, 188, 2189-2197.	0.8	102
57	Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. Journal of Immunological Methods, 2011, 373, 54-62.	1.4	15
58	Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant. PLoS ONE, 2011, 6, e16333.	2.5	281
59	A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis. Science Translational Medicine, 2010, 2, 53ra74.	12.4	268
60	Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids and Surfaces B: Biointerfaces, 2010, 75, 123-132.	5.0	97
61	A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines. PLoS ONE, 2010, 5, e13677.	2.5	137
62	Identification and characterization of novel recombinant vaccine antigens for immunization against genitalChlamydia trachomatis. FEMS Immunology and Medical Microbiology, 2009, 55, 258-270.	2.7	41
63	Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis. Journal of Immunology, 2008, 181, 7948-7957.	0.8	157
64	Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4⁺T Cells. Infection and Immunity, 2007, 75, 4648-4654.	2.2	187
65	Immunization with a Polyprotein Vaccine Consisting of the T-Cell Antigens Thiol-Specific Antioxidant, Leishmania major Stress-Inducible Protein 1, and Leishmania Elongation Initiation Factor Protects against Leishmaniasis. Infection and Immunity, 2002, 70, 4215-4225.	2.2	133
66	Expression Cloning of an Immunodominant Family of Mycobacterium tuberculosis Antigens Using Human Cd4+ T Cells. Journal of Experimental Medicine, 2000, 191, 551-560.	8.5	116